Bioveris — Shareholder Meeting (October 2004)
38 slides from Bioveris's shareholder meeting presentation, Oct 20, 2004

Slide 1: Annual Meeting of Stockholders
Annual Meeting of Stockholders October 19, 2004

Slide 2: Forward-Looking Statement Disclaimer
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about business prospects, utility of the Company’s technology and products, market opportunities and growth, revenue growth and new business or produ

Slide 3: An Integrated Healthcare Company
An Integrated Healthcare Company Focused on achieving continuous invoicing capacity from products and services in the field of immunology

Slide 4: BioVeris: A diagnostic company
BIOVERIS A diagnostic company Non-clinical Diagnostics Clinical Diagnostics Life Science Biodefense Select agents / DOD Physician Office / Hospital / Clinic Historical Perspective

Slide 5: An integrated healthcare company
Dx Rx Licensing-in Marketing R&D Manufacturing Expand and leverage BIOVERIS An integrated healthcare company Non-clinical Diagnostics Clinical Diagnostics Clinical Prophylaxis Life Science Immunogenicity Biodefense Select agents/DOD Physician Office/ Hospital / Clinic Vaccine panel Vaccines (Synthet

Slide 6: BioVeris Overview
BioVeris stock distributed to IGEN stockholders BioVeris became an independent, publicly-traded (NASDAQ) company (Ticker: BIOV ) Formed in 2003, as a wholly-owned subsidiary of IGEN International, Inc. On effective date of Roche / IGEN merger: 26.7 million shares outstanding (22% directors and manag

Slide 7: ECL-Based Systems
ECL-Based Systems MICROTubes Reagents Instrumentation and consumables for the life science, biodefense and first responder markets M1M M384

Slide 8: Growing Product Sales
Revenue (in millions of dollars) $7.7 $8.9 FY 1999 - 2004 CAGR 31% $12.1 $16.5 $4.9 $18.7 Growing Product Sales

Slide 9: Instrument and Consumable Sales
Revenue (in millions of dollars) $8.9 $12.1 $16.5 $18.7 Instrument and Consumable Sales

Slide 10: Markets & Applications
Clinical Prophylaxis Clinical diagnostics Non-clinical diagnostics Markets & Applications Blockbuster applications Synthetic carbohydrate conjugate vaccines Vaccines Killer applications Vaccine diagnostic panel Select agents/ Infectious disease Physician Office/Hospital/Clinic First Responders Speci

Slide 11: BioVeris History in Biodefense
First instruments purchased by USAMRIID and APG Evaluation of ability to detect select agents DOD asks for assistance in manufacturing detection assays $23 MM DOD contract to provide tests Systems used in ricin investigations STORM initiated On-site testing at G8 Euro Summit & Athens Olympics >250,0

Slide 12: USAMRIID endorsement of ECL technology
“This technology (ECL) will prove: itself to be an important 4 component of an integrated JUSAMRIID} approach to identification of potential biological weapons, both

Slide 13: Detection of Select Agents in Complex Samples
AGENTS SAMPLES Detection of Select Agents in Complex Samples Anthrax Ricin Botulinum toxins Plague Smallpox Tularemia E. coli O157 Salmonella Listeria Soil Water Air Plant extracts Food and dairy products Blood / Serum Fecal material Cell culture medium Organic solutions Biodefense/Industrial Testin

Slide 14: Multiple Ongoing Biodefense Programs
Multiple Ongoing Biodefense Programs Automated Biological Agent Testing System (ABATS) High throughput automation Stations of Robotic Monitoring (STORM) Smaller, more portable version of ABATS CRADA’s with Brooks Army Medical Center / USAMRIID / U.S. Air Force Product Development Joint Service Insta

Slide 15: Product Launch: M-SERIES M1M Analyzer
Product Launch: June 2004 M-SERIES M1M Analyzer Integrated plate shaking Supports tubes in racks Ruggedized design External touch-screen PC Compact footprint – Dimensions: 38 cm (W) X 38 cm (D) X 30 cm (H) Weight: ~ 15 Kg (excluding PC) Low power consumption: < 45 Watts

Slide 16: One Step Assays FASTubes & BV MICROTubes
One Step Assays FASTubes & BV MICROTubes ™ All assay reagents freeze-dried in one tube (antibodies and beads) Add sample and incubate 15 minute assay High sensitivity Wide dynamic range FASTubes for use with the BioVeris Detection System MICROTubes for use with M-SERIES

Slide 17: First Responders Biodefense Opportunities
First Responders Biodefense Opportunities U.S. Public Safety Sites Fire Departments 26,000 Police Departments 19,000 Hospitals 6,000 Universities

Slide 18: Biodefense – First Responders
Biodefense – First Responders Maintain readiness Immediate post-exposure Reduce morbidity & mortality

Slide 19: Life Science
Biology Genomics Proteomics Synthesis Screening Testing Safety Efficacy ADME/TOX Manufacturing Quality Distribution Basic Research Disease Discovery Drug Discovery Drug Development Clinical Trials Manufacturing/ Post Market Surveillance Life Science

Slide 20: Select Life Science Customers
Merck KGaA Boehringer Ingelheim Wyeth Ayerst 3M Max Planck Institute NIH & NCI Eli Lilly Merck & Co. Genentech Schering- Plough Zymogenetics Bayer Schering AG Biogen IDEC Pharma. Baxter Centecor J&J Human Genome Sci. Aventis Pfizer GlaxoSmithKline AstraZeneca Novartis Bristol-Myers Squibb Amgen Sele

Slide 21: Immunogenicity Testing of Protein-based Therapeutics
Allergic reaction, anaphylaxis Reduced efficacy Autoimmunity to endogenous protein 54 approved / hundreds in development Monoclonal antibodies (Herceptin, Enbrel, Avastin) Hormones (insulin, growth hormone) Enzymes (factor VIII, streptokinase) Cytokines (IFN , IFN , epoetin) 1. Clinical consequences

Slide 22: Immunogenicity Testing of Protein-based Therapeutics
Are antibodies present? Are the antibodies specific? What type(s) of antibody are present and do they interfere with binding events (cell function or target)? Screen - Confirm - Characterize – Immunogenicity Testing of Protein-based Therapeutics

Slide 23: The BioVeris Advantage
Measurement of low affinity antibodies High sensitivity Measure antibodies in presence of drug Eliminates need to re-qualify labeled reagents mid-study The BioVeris Advantage Reduced wash steps Sensitive label Large capture capacity / solution phase Stable Label Immunogenicity Testing of Protein-bas

Slide 24: Personalized Immune Status
® National Partnership for Immunization Personalized Immune Status “To vaccinate or not to vaccinate?” that is the question

Slide 25: Personalized Immune Status
Determined Through Diagnostic Testing Across All Segments of the Population RESULT Highest Product Demand Greatest Vaccine Sales Best Public Health and Quality of Life Testing Reveals Lack of Protection Available from Existing and Future Vaccines Personalized Immune Status

Slide 26: CDC's Immunization Registry Strategic Plan
Health information systems are the cornerstone of immunization delivery in the 21 st century Maximize protection against vaccine-preventable diseases by leading the advancement of immunization information systems Immunization Registry Strategic Plan (2003) CDC VISION STATEMENT MISSION STATEMENT CDC’

Slide 27: Health Information Technology Initiative Goals
Bring information tools to the point of care (physician offices and hospitals) Build health information infrastructure, so that clinicians have access to critical health care information Give consumers more access and involvement in health decisions Expand capacity for public health monitoring and i

Slide 28: Market Segments & Channels
Hospital births / ObGyn Pediatric network School entry Specific grade levels College entry College health plans Medicare AARP Local senior citizen centers Nursing homes Parents accessed through their children by pediatric network Women via gynecologists Travelers Government-sponsored activities: Mil

Slide 29: Personalized Immune Status and Vaccination Services
Diagnostic testing - Immunoassay / Nucleic acid (PCR) Vaccine Diagnostic Panel Physician / Healthcare Provider CDC ACIP Personalized Immune Status: - Individual - Population / specific groups Immunization Registry Vaccine Status Database Assist in vaccine recommendation / decision-making Personalize

Slide 30: Personalized Immune Status and Vaccination Services
Diagnostic testing - Immunoassay / Nucleic acid (PCR) Vaccine sales Subsidy / funding Mandate – vaccine benefits Economic incentive to create / supply vaccines Personalized Immune Status: - Individual - Population / specific groups Assist in vaccine recommendation / decision-making Vouchers – reimbu

Slide 31: Who Benefits?
Improved health and quality of life Greater demand for products Better healthcare / expanded business Prevention costs less than treatment Better monitoring for biodefense, senior citizens and general public welfare Reduce nosocomial infections and biohazard risks Reduce biohazard risks General publ

Slide 32: Report of the CBACI National Vaccine Strategy Working Group
Report of the CBACI National Vaccine Strategy Working Group Chemical & Biological Arms Control Institute Vaccines “Today, we face natural and potentially “introduced” biological threats for which vaccines could be an important part of the solution … if we can make them available. While vaccines are

Slide 33: A Booster Shot for Vaccines
Business Week October 25, 2004 “A Booster Shot for Vaccines” New technology could speed development and keep the medicine chest stocked. “The world hasn’t made vaccines a high enough priority… Yet, the benefits of vaccines are clear: Immunizations save the U.S. alone roughly $40 billion each year in

Slide 34: Carbohydrate Vaccines
vaccines have generally been made from weakened or dead pathogens or from immunogenic molecules obtained from microorganisms – which are often difficult to isolate from their natural sources and may present problems with purity and contamination. an opportunity has arisen in the form of chemical car

Slide 35: Synthetic Carbohydrate Conjugate Vaccines: Advantages
Novel chemistry with proven technology Higher product purity Greater manufacturing consistency Better product characterization to facilitate regulatory approval More adaptable to chemical modification to enhance immunogenicity More cost effective to manufacture SYNTHETIC CARBOHYDRATE CONJUGATE VACCI

Slide 36: Children's Hospital & Research Center at Oakland
Children’s Hospital & Research Center At Oakland Exclusive option to negotiate Sponsored research Commercial rights for prevention and diagnosis Unique vaccine candidate for Neisseria meningitidis serogroup B (meningitis) Significant unmet medical need

Slide 37: Conclusion
Conclusion Establishing a focused, expandable and leveraged business model Directing the processes to successfully implement these plans Allocating resources required to succeed (physical and personal assets)

Slide 38: Annual Meeting of Stockholders
Annual Meeting of Stockholders October 19, 2004
Source: SEC EDGAR · 8-K filed Oct 20, 2004